Clinical TrialOct 23, 2026, 06:07 AM
Evaxion's EVX-01 Cancer Vaccine Shows 89% Target Precision, Sustained Response
AI Summary
Evaxion A/S announced new three-year immune and clinical outcome data for its personalized cancer vaccine, EVX-01, in a Phase 2 trial for advanced melanoma. The data highlights an 89% vaccine target precision and sustained T-cell and clinical responses, with all patients maintaining their response through the third year. These findings supplement previous two-year data showing a 75% Objective Response Rate and reinforce the potential of Evaxion's AI-Immunology™ platform.
Key Highlights
- Evaxion's EVX-01 personalized cancer vaccine shows 89% vaccine target precision in Phase 2 trial.
- Sustained T-cell and clinical responses observed at three-year follow-up in advanced melanoma patients.
- All patients maintained clinical response through year three with no tumor progression.
- EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent specific T-cell responses.
- Two-year data showed a 75% Objective Response Rate with 25% complete response.
Price Impact
More from EVAX